FDA approves clinical trial of artificial pancreas

Monday, March 19, 2012 03:46 PM

The FDA has approved the first outpatient artificial pancreas trial in the U.S., which will be funded by JDRF, a global organization focused on type 1 diabetes research.

The study will test an artificial pancreas (AP) system's ability to function outside a hospital setting, and is similar to the current outpatient trials being conducted in Europe. The study is part of the first outpatient trials using an approach developed by the JDRF-supported Artificial Pancreas Consortium, an international research group including teams from Montpellier University Hospital in France, the Universities of Padova and Pavia in Italy, the University of Virginia in Charlottesville and University of California in Santa Barbara.

"While this is a small feasibility study, this is a major step forward in the field of artificial pancreas research and we congratulate the researchers and the FDA on this important milestone,” said Aaron Kowalski, Ph.D., assistant vice president of treatment therapies, JDRF.

The approval of the milestone study follows a major 18-month long effort by JDRF and allies to ensure a clear and reasonable regulatory pathway for outpatient artificial pancreas studies, and ultimately for AP systems to be approved and made available by the FDA. JDRF-funded studies have shown improved clinical outcomes from early trials of prototype AP systems

In December 2011, the FDA met its promised deadline and released draft guidance for AP systems. JDRF recently completed an evaluation of the draft FDA AP guidance, and submitted comments to FDA on March 3, 2012.  JDRF believes that the draft contains many positive elements that will encourage R&D of artificial pancreas technologies and lead to their eventual availability in the U.S.

"While there were some areas of concern in the guidance, we have begun a dialogue with FDA about these issues, and we will continue to urge the agency to revise these in the guidance before it is finalized so that we will continue to see more outpatient trials approved, and people with diabetes will ultimately have access to these lifesaving technologies as soon as possible," added Kowalski.

JDRF and the National Institutes of Health's (NIH) Special Diabetes Program have funded groundbreaking work in recent years to advance AP system research and development.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs